Back to Search
Start Over
Nobody dares stopping clinical research, not even COVID-19
Nobody dares stopping clinical research, not even COVID-19
- Source :
- npj Breast Cancer, Vol 7, Iss 1, Pp 1-3 (2021)
- Publication Year :
- 2021
- Publisher :
- Nature Portfolio, 2021.
-
Abstract
- In the global health emergency caused by the COVID-19, clinical trial management has proven to be critical for the pharmaceutical industry, sponsors, and healthcare professionals. Our experience as a sponsor managing interventional oncology clinical studies has provided us with some data and insights. Though limited by sample size, our data emphasize the importance of quickly adopting measures that first prioritize patient safety and data validity, then consider contingency measures such as telemedicine, virtual medical review, and remote monitoring. Successful adaptations of healthcare and patient management in response to COVID-19 have been fundamental to ensuring continuing clinical cancer research.
- Subjects :
- Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Subjects
Details
- Language :
- English
- ISSN :
- 23744677
- Volume :
- 7
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- npj Breast Cancer
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.33b48eb9a9dd438c9f6dd121fdf66906
- Document Type :
- article
- Full Text :
- https://doi.org/10.1038/s41523-021-00249-1